Core Insights - The white paper by BullFrog AI discusses the importance of data harmonization in biopharma, emphasizing how the company's bfPREP technology transforms noisy biomedical data into standardized, AI-ready datasets [1][2][3] Group 1: Data Harmonization - BullFrog AI's bfPREP technology addresses the challenges of fragmented and unstructured biomedical data, enabling the creation of clean, analysis-ready datasets [2][3] - The white paper outlines a practical framework for data harmonization based on three pillars: engineering clinically meaningful derived features, producing reliable categorical variables and harmonized schemas, and transforming unstructured clinical documents into analysis-ready tables [2] Group 2: AI and Machine Learning Value - The true value of AI and machine learning in life sciences is realized through data harmonization, which allows teams to focus on interpreting results and making decisions rather than data wrangling [3] - BullFrog AI aims to reduce clinical trial failure rates by providing reliable datasets that enhance the efficiency of drug development processes [3][4]

Core Insights - Cognition Therapeutics, Inc. is advancing its investigational drug zervimesine (CT1812) for treating dementia with Lewy bodies (DLB) and has conducted a Type C meeting with the FDA to discuss the Phase 2b study [1][2] Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related neurodegenerative disorders [4] - The company has completed Phase 2 studies for zervimesine in DLB and mild-to-moderate Alzheimer's disease, with ongoing studies supported by an $81 million grant from the National Institute of Aging [4] Drug Development - Zervimesine is an oral, once-daily pill aimed at treating CNS diseases, specifically targeting the toxic effects of Aβ and ɑ-synuclein proteins that contribute to neurodegeneration [2] - The drug has shown promise in interrupting the toxic effects of these proteins, potentially slowing disease progression and improving patient quality of life [2] Regulatory Engagement - The FDA meeting was described as productive, focusing on clinically meaningful endpoints for the upcoming Phase 2b study [2] - The company anticipates receiving meeting minutes from the FDA later this quarter, indicating ongoing communication to advance clinical development [2]

Core Viewpoint - Dynacor Group Inc. has announced a monthly dividend of C$0.01333 per common share, amounting to C$0.16 annually, payable on February 17, 2026, to shareholders of record as of February 9, 2026 [1]. Group 1: Dividend Announcement - The Board of Directors approved a monthly dividend of C$0.01333 per common share for February 2026 [1]. - The dividend payment qualifies as an "eligible dividend" for Canadian income tax purposes [2]. - Future dividend payments and increases will depend on the Corporation's financial results and other relevant factors [2]. Group 2: Company Overview - Dynacor Group is an industrial ore processing company focused on producing gold from artisanal miners [3]. - The company has established a responsible mineral supply chain with strict traceability and audit standards [3]. - Dynacor operates the Veta Dorada plant and owns a gold exploration property in Peru, with plans to expand into West Africa and Latin America [3]. Group 3: Social Responsibility - The premium paid for Dynacor's PX Impact® gold supports the Fidamar Foundation, which invests in health and education projects for artisanal mining communities in Peru [4].

9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populationsNo Bria-IMT™ related discontinuations reported to dateBria-IMT regimen continues under Fast Track Designation from US FDA PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stag ...

Core Insights - Terra Clean Energy Corp. supports Utah's "Mission Critical" strategy for critical minerals, aiming to make Utah the leading destination for mineral extraction and processing in the U.S. [1] - The strategy includes the approval of five mining projects in 2026 and the establishment of a national lab by 2031 [1][2] - Uranium has been added to the U.S. Government's critical minerals list, which is expected to influence federal and state policies [2] Company Overview - Terra Clean Energy Corp. is a Canadian uranium exploration and development company, currently developing the South Falcon East uranium project with an inferred resource of 6.96 million pounds of uranium [3] - The company also has past producing uranium mines in Utah and exploration properties in Wyoming [3] Industry Context - The "Mission Critical" initiative aims to capture 25% of the critical mineral market share and reduce permitting timelines by 50% [2] - The initiative also seeks to ensure that 50% of minerals extracted in Utah are processed within the state [2] - CEO Greg Cameron believes that 2026 will be a pivotal year for uranium, with a focus on expanding Terra's portfolio of U.S. uranium assets, particularly in Utah [2]

Core Insights - Gilat Satellite Networks Ltd. has received a multimillion-dollar order from a large global avionics company for its Sidewinder electronically steered antenna terminals, with deliveries expected within the next six months [1][2]. Group 1: Product and Technology - The Sidewinder ESA platform is gaining momentum in the inflight connectivity market, driven by demand for advanced solutions that offer high performance in a lightweight configuration [2][4]. - Sidewinder ESA is designed for various aviation sectors, including commercial, business, VIP, government, and military, supporting high throughput satellite networks for reliable, high-speed connectivity [3][4]. - The technology features electronic beam steering, which enhances satellite acquisition speed, reliability, and reduces maintenance compared to traditional mechanically steered antennas [3]. Group 2: Company Overview - Gilat Satellite Networks is a leading global provider of satellite-based broadband communications, with over 35 years of experience in developing technology solutions for satellite and ground connectivity [4][5]. - The company offers a comprehensive portfolio that includes software-defined platforms, high-performance satellite terminals, and advanced antennas, catering to both commercial and defense markets [5][6]. - Gilat's products support multiple applications, including government and defense, inflight connectivity, cellular backhaul, and critical infrastructure, while adhering to stringent service level requirements [6].

Core Insights - Cardiff Oncology, Inc. announced positive results from the CRDF-004 Phase 2 clinical trial, demonstrating that onvansertib combined with FOLFIRI/bevacizumab (bev) shows dose-dependent improvements in overall response rates and progression-free survival (PFS) in patients with RAS-mutated metastatic colorectal cancer (mCRC) [1][3][4] Group 1: Clinical Trial Results - The trial showed that the 30 mg dose of onvansertib with FOLFIRI/bev is selected for further registrational trials based on its efficacy [2][3] - In the intent-to-treat analysis, onvansertib with FOLFIRI/bev outperformed both standard of care (SoC) regimens, with a confirmed objective response rate (ORR) of 44.4% for the 30 mg dose [1][3] - Median PFS for the 30 mg onvansertib group was not reached, indicating a potential benefit over SoC [3][4] Group 2: Safety and Tolerability - Onvansertib was reported to be safe and well-tolerated, with no significant additive toxicity observed in the trial [1][3] - Grade 3 or higher adverse events were infrequent, with neutropenia being the most common treatment-emergent adverse event [5] Group 3: Future Plans - Cardiff Oncology plans to initiate a registrational program later this year, pending finalization of trial design in consultation with the FDA [2][3] - The company expects to provide final data and registrational plans in the first half of 2026 [1][3] Group 4: Industry Context - There is a significant unmet need for improved first-line treatment options for patients with RAS-mutated mCRC, as current treatments have not significantly advanced in over two decades [5] - Onvansertib's novel mechanism of action and promising preliminary results support the need for further investigation in a large Phase 3 trial [5]

New Touch controllers bring reliable touch sensing to both very small and very large display formats in modern automotive applicationsCHANDLER, Ariz., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Microchip Technology (Nasdaq: MCHP) has again expanded its maXTouch® M1 family of touchscreen controllers to bring reliable and secure touch detection to an even greater range of automotive displays, now covering free-form widescreen format displays up to 42 inches down to small compact screens in the 2 to 5 inch range. The A ...

FORT WORTH, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- American Airlines Group Inc. (NASDAQ: AAL) today reported its fourth-quarter and full-year 2025 financial results, including: Record fourth-quarter revenue of $14.0 billion and record full-year revenue of $54.6 billionThe government shutdown negatively impacted revenue in the fourth quarter by approximately $325 million Fourth-quarter and full-year GAAP net income of $99 million and $111 million, or $0.15 and $0.17 per diluted share, respectivelyExcluding ...

DUBAI, United Arab Emirates, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Swvl Holdings Corp (“Swvl” or the “Company”) (Nasdaq: SWVL), the leading provider of technology-enabled mass mobility solutions, today announced the launch of its operations in Kuwait, marking a key milestone in the Company’s regional expansion strategy. The launch is anchored by a $2.2 million multi-year contract, reinforcing Swvl’s growing presence across high-value Gulf Cooperation Council (GCC) markets. The Kuwait rollout will see Swvl deplo ...